NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
94.22
Dollar change
-4.45
Percentage change
-4.51
%
IndexRUT P/E- EPS (ttm)-0.37 Insider Own2.80% Shs Outstand5.46M Perf Week-3.77%
Market Cap514.01M Forward P/E9.97 EPS next Y9.45 Insider Trans-13.60% Shs Float5.30M Perf Month-9.95%
Enterprise Value680.54M PEG- EPS next Q2.27 Inst Own95.01% Short Float3.48% Perf Quarter-21.20%
Income-1.97M P/S2.13 EPS this Y-17.35% Inst Trans1.30% Short Ratio1.93 Perf Half Y-28.21%
Sales240.98M P/B3.22 EPS next Y9.21% ROA-0.45% Short Interest0.18M Perf YTD-28.55%
Book/sh29.30 P/C18.81 EPS next 5Y-5.81% ROE-1.29% 52W High155.12 -39.26% Perf Year6.85%
Cash/sh5.01 P/FCF12.08 EPS past 3/5Y- - ROIC-0.79% 52W Low84.32 11.74% Perf 3Y-52.42%
Dividend Est.0.64 (0.68%) EV/EBITDA16.66 Sales past 3/5Y9.34% 15.41% Gross Margin55.32% Volatility5.06% 4.35% Perf 5Y-57.61%
Dividend TTM0.64 (0.68%) EV/Sales2.82 EPS Y/Y TTM99.25% Oper. Margin6.78% ATR (14)4.79 Perf 10Y3.68%
Dividend Ex-DateMay 30, 2025 Quick Ratio0.47 Sales Y/Y TTM11.47% Profit Margin-0.82% RSI (14)37.47 Recom2.50
Dividend Gr. 3/5Y0.00% 0.00% Current Ratio0.63 EPS Q/Q97.23% SMA20-4.48% Beta0.88 Target Price121.67
Payout- Debt/Eq1.21 Sales Q/Q5.49% SMA50-13.59% Rel Volume3.14 Prev Close98.67
Employees730 LT Debt/Eq0.56 EarningsMay 28 BMO SMA200-23.40% Avg Volume95.41K Price94.22
IPOFeb 29, 1984 Option/ShortNo / Yes EPS/Sales Surpr.-1.89% 0.38% Trades Volume299,233 Change-4.51%
Date Action Analyst Rating Change Price Target Change
Aug-28-24Initiated Wells Fargo Underweight $120
Jan-04-24Upgrade Evercore ISI In-line → Outperform $100 → $125
Jan-04-21Downgrade Evercore ISI Outperform → In-line $300
Nov-10-20Initiated KeyBanc Capital Markets Sector Weight $287
Oct-02-20Initiated JP Morgan Neutral $260
Dec-04-19Initiated Jefferies Buy
Aug-26-19Initiated Evercore ISI Outperform $250
Jun-10-16Downgrade Sidoti Buy → Neutral
May-28-25 09:15AM
08:23AM
08:00AM
May-15-25 05:25PM
May-14-25 05:45PM
05:35PM Loading…
May-13-25 05:35PM
May-08-25 08:45AM
Apr-07-25 03:00PM
Apr-03-25 03:51PM
Mar-26-25 12:00PM
Feb-13-25 08:31AM
Feb-11-25 12:20PM
Feb-04-25 09:15AM
08:17AM
08:00AM
01:15PM Loading…
Jan-17-25 01:15PM
Jan-06-25 03:00PM
Nov-07-24 09:20AM
08:27AM
08:00AM
Oct-15-24 05:02PM
Oct-02-24 02:00PM
Aug-26-24 12:20PM
12:00PM
Aug-16-24 07:51AM
Aug-05-24 08:15AM
08:00AM
Jul-31-24 09:14AM
Jul-08-24 02:00PM
Jun-05-24 11:53AM
06:38AM Loading…
06:38AM
06:21AM
06:00AM
May-31-24 06:00AM
May-22-24 06:00AM
Apr-08-24 08:00AM
Apr-04-24 06:24PM
Apr-01-24 10:27AM
Mar-15-24 07:00AM
Feb-19-24 10:23AM
Feb-05-24 09:20AM
08:36AM
08:22AM
08:00AM
Jan-08-24 08:00AM
Jan-04-24 03:00PM
Jan-03-24 08:00AM
Dec-14-23 10:47AM
Nov-06-23 09:10AM
08:13AM
08:00AM
Oct-16-23 03:00AM
Oct-03-23 08:00AM
Sep-22-23 08:09AM
06:20AM
Sep-15-23 01:10AM
Sep-13-23 01:37PM
Sep-11-23 11:21AM
Aug-24-23 04:02PM
Aug-10-23 01:32AM
Aug-03-23 09:35AM
08:27AM
08:00AM
Jul-31-23 07:50AM
Jul-05-23 03:00PM
Jun-21-23 08:00PM
11:50AM
May-25-23 09:25AM
08:14AM
08:00AM
May-22-23 01:16PM
May-02-23 06:23AM
Apr-26-23 08:00PM
Apr-03-23 06:15PM
06:00PM
07:42AM
Mar-13-23 08:00AM
Mar-09-23 08:00AM
Feb-21-23 05:36AM
Feb-14-23 09:00AM
Feb-13-23 12:45PM
08:00AM
Feb-06-23 09:55AM
08:36AM
Feb-01-23 12:43PM
06:43AM
Jan-27-23 06:00PM
Jan-19-23 06:15PM
Jan-17-23 04:33PM
Jan-13-23 06:00PM
Jan-12-23 09:40AM
Jan-11-23 06:26AM
Jan-09-23 06:15PM
Jan-03-23 05:00PM
Dec-28-22 06:51AM
05:20AM
Dec-18-22 04:48PM
Dec-16-22 11:59AM
Nov-23-22 12:20PM
Nov-17-22 08:04AM
Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sakys JohnCFOJun 21 '25Option Exercise95.821,03699,27015,498Jun 25 09:14 AM
Archbold Brian DavidSVP OperationsJun 21 '25Option Exercise95.8284480,8722,792Jun 25 09:05 AM
Owens Gary MPresident and CEOJun 21 '25Option Exercise95.823,301316,30254,022Jun 24 10:12 AM
Owens Gary MPresident and CEOJun 18 '25Option Exercise92.998,707809,66454,531Jun 20 05:39 PM
Archbold Brian DavidSVP OperationsJun 18 '25Option Exercise92.992,556237,6823,114Jun 20 05:31 PM
Sakys JohnCFOJun 18 '25Option Exercise92.992,840264,09215,705Jun 20 05:22 PM
Owens Gary MPresident and CEOJun 15 '25Option Exercise0.004,426047,763Jun 18 11:27 AM
Owens Gary MPresident and CEOJun 16 '25Sale97.121,939188,31245,824Jun 18 11:27 AM
Archbold Brian DavidSVP OperationsJun 15 '25Option Exercise0.001,03001,030Jun 18 11:13 AM
Archbold Brian DavidSVP OperationsJun 16 '25Sale97.1247245,840558Jun 18 11:13 AM
Sakys JohnCFOJun 15 '25Option Exercise0.00793012,839Jun 18 10:59 AM
Sakys JohnCFOJun 16 '25Sale97.1264262,35012,865Jun 18 10:59 AM
Archbold Brian DavidOfficerJun 16 '25Proposed Sale97.1247245,840Jun 16 03:49 PM
Owens Gary MOfficerJun 16 '25Proposed Sale97.121,939188,311Jun 16 03:47 PM
Sakys JohnOfficerJun 16 '25Proposed Sale97.1264262,350Jun 16 03:40 PM
Owens Gary MPresident and CEOMar 19 '25Option Exercise122.9821,0002,582,58064,337Mar 24 01:38 PM
Owens Gary MPresident and CEOMar 19 '25Sale123.9121,0002,602,11043,337Mar 24 01:38 PM
Owens Gary MOfficerMar 19 '25Proposed Sale123.9121,0002,602,119Mar 19 04:12 PM
Owens Gary MPresident and CEOOct 28 '24Sale113.622,518286,08545,888Oct 29 08:18 PM
Owens Gary MPresident and CEOOct 29 '24Sale111.982,551285,65143,337Oct 29 08:18 PM
Owens Gary MOfficerOct 29 '24Proposed Sale111.982,551285,652Oct 29 03:47 PM
Owens Gary MOfficerOct 28 '24Proposed Sale113.622,518286,086Oct 28 03:12 PM
Archbold Brian DavidSVP OperationsSep 13 '24Sale125.001,499187,3750Sep 16 12:14 PM
Archbold Brian DavidOfficerSep 13 '24Proposed Sale125.001,499187,381Sep 13 04:35 PM
Sakys JohnCFOSep 01 '24Option Exercise0.001,037012,500Sep 06 12:46 PM
Owens Gary MPresident and CEOSep 01 '24Option Exercise0.003,301038,292Sep 06 12:21 PM
Archbold Brian DavidSVP OperationsSep 01 '24Option Exercise0.0084501,885Sep 06 12:12 PM
Sullivan John JamesDirectorSep 01 '24Option Exercise0.001,074027,878Sep 06 11:53 AM
Tripeny R TonyDirectorSep 01 '24Option Exercise0.001,07402,679Sep 06 11:43 AM
Ladiwala Shiraz ShabanaliDirectorSep 01 '24Option Exercise0.001,57403,074Sep 06 11:35 AM
Hall ShannonDirectorSep 01 '24Option Exercise0.001,07402,785Sep 06 11:28 AM
Alltoft Jennifer SadieDirectorSep 01 '24Option Exercise0.001,07403,474Sep 06 11:22 AM
Capone Mark ChristopherDirectorAug 15 '24Option Exercise0.007240724Aug 19 11:08 AM